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DHEA - Brass Ring or Red Herring? 
erontologists want so much to believe in DHEA. Early G enthusiasm for DHEA - the celebrity steroid whose 
exploits are the focus of an impressive proportion of pop- 
science books on cures for aging and the proud possessor of 
hectares of shelf space in health food stores - seemed to be on 
fairly steady ground, at least in comparison with the scientific 
evidence for the antigeric properties attributed to melatonin 
and royal jelly. Epidemiological evidence suggested associa- 
tions between low DHEA levels and high relative risks for 
breast cancer' and cardiovascular disease? Studies of the 
metabolic effects of DHEA suggested that it might help to 
protect against the atherogenic effects of adult-onset diabetes 
and obesity.3 A single injection of DHEA into old mice was 
said to correct many aspects of immunosenescence, including 
poor primary and secondary antibody responses to neoanti- 
g e m 4  Aging mice given high doses of DHEA in their food 
were lighter, had lower rates of kidney failure, and were 
cancer-resistant.' Besides, there was so much of it in young 
adults, and its levels declined so convincingly in older people, 
that it just had to do  something good, didn't it? 
New data and new arguments have begun to temper the 
excess of enthusiasm for this mysterious steroid. Follow-up 
studies have shown that high DHEA levels in mid-life do not, 
in the longer term, predict resistance to mortality from car- 
diovascular illness in men6 or women.' Although high DHEA 
levels may be associated with resistance to breast cancer 
among premenopausal women, they seem to confer greater 
breast cancer risk in postmenopausal ~ o m e n . ~ . ~  High levels 
of DHEA do not seem to convey protection against cognitive 
failure" or obesity or glucose intolerance." Thus the epide- 
miological evidence associating high levels of serum DHEA 
with resistance to the diseases and disabilities of old age is 
now tenuous at best. 
Replications of the initial dramatic reports of immunore- 
juvenation in mice have been slow in coming, and interpre- 
tation of the rodent data has been complicated by the realiza- 
tion that rodents neither make DHEA nor retain ingested 
DHEA. Our own ongoing intervention trial of lifelong oral 
DHEA-S in genetically heterogeneous mice has, to date, 
shown no evidence for positive effects of this steroid on 
immunological responses or on survival (Miller et al., unpub- 
lished data). Similarly, clinical studies of DHEA as a poten- 
tiator of immune responses of middle-aged or older people to 
vaccination have been disappointing, providing little or no 
evidence for clinical efficacy in trials using influenza or teta- 
nus  vaccine^.'^^'^ DHEA administration to postmenopausal 
women for 3 weeks was found to have no positive effects on 
T cell proliferation or cytokine production, although the 
function of natural killer cells in the blood was increased 
~ignificantly'~ in this double-blind cross-over study. A single- 
blind study in which DHEA was administered daily for 20 
weeks to a group of older men (average age 64 years) pro- 
duced no consistent or convincing changes in T cell respon- 
siveness; the transient positive results claimed by these au- 
thors seem more likely to represent chance fluctuations over a 
long series of multiple c o r n p a r i s ~ n s , ~ ~  and the study did not 
include parallel studies of placebo control subjects. 
Long-term (6 to 12 month) administration of DHEA to 
volunteers has little or no effect on objective measures of 
physiological health.'s*'6 Thus, a 6-month double-blind 
study of DHEA given at  50 mg/day to 30 volunteers aged 40 
to 70 years found no effects on lipid profiles, insulin sensitiv- 
ity, or body fat; the exception was a small decline in high 
density lipoprotein levels in women. A second study using 
DHEA at 100 mg/day for 12 months again found no change 
in lipid or apolipoprotein levels, lumbar muscle strength, 
glucose or insulin levels, or bone mineral density. Knee mus- 
cle strength increased in the men by about 15%, with the 
placebo effect responsible for half the change; knee strength 
decreased in the women. Androgen levels increased signifi- 
cantly among women in both of these studies, exceeding the 
normal range in the longer study. The only consistent dra- 
matic effect was a psychological one: 67% of the men and 
84% of the women in the 1-year study reported improve- 
ments in their own sense of well-being while ingesting DHEA. 
See also p 1395 
The current status of DHEA research suggests that learn- 
ing more about the basic biology of steroid action should take 
precedence over the ever-alluring temptation to rush into 
clinical trials. Hornsby's review suggests a number of ques- 
tions whose answers might help to point the way to a more 
judicious selection of physiological targets for intervention. 
The distribution among tissues of DHEA sulfatases, the abil- 
ity of target tissues to transform DHEA into active metabo- 
lites, the source of and role for DHEA in the central nervous 
system, the interactions between DHEA and other steroids 
whose levels (and actions) may vary with age and gender, and 
the potential role of DHEA in peroxisome regulation - each 
of these areas is likely to reward additional investigation, and 
could help to guide a second, and possibly more productive, 
wave of clinical investigations. 
Hornsby's review also provides an admirable example of 
the place for comparative biology in experimental aging 
research. One implication is fairly obvious: those of us who 
work in animal models need to remain watchful for excep- 
tions to our tacit assumption that mice are simply small 
nocturnal people with prominent whiskers. Much of what we 
learn about the biochemistry, physiology, neurobiology, pa- 
thology, and genetics of mice, rats, dogs, and cats can be 
applied usefully, with appropriate caution and confirmation, 
to human biology, but much of it cannot. It is not simply that 
reports of DHEA administration to rats and mice will need to 
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be re-labeled “pharmacology” rather than “hormone- 
replacement” studies, but rather that investigations of the 
action of this steroid in animals will need to take note of 
species-specific peculiarities in its uptake, transport, metabo- 
lism, excretion, and cellular actions, which may be very 
different in species that differ more than 100-fold in the 
natural levels of circulating DHEA. (The demonstration that 
nearly all common strains of laboratory mice lack the en- 
zymes needed to synthesize melatonin’’ has led to a similar 
reassessment of the reported effects of pineal transplants and 
melatonin inhibitors in aging mice.) 
The second implication is less discouraging: the restric- 
tion of DHEA to humans, chimps, and their close relatives, 
while arguing against an important general role of DHEA in 
mammalian aging, is consistent with the idea that this hor- 
mone may indeed play a key role in the timing of human 
life-history events. Evolution of long-lived primates has in- 
volved strong selection for genes that delay sexual matura- 
tion and for genes that postpone diseases to ages beyond 
those of full reproductive maturity. Physiological traits that 
sharply distinguish humans from their shorter-lived cousins - 
such as the unexplained predominance of DHEA among 
circulating human steroids, and its careful age-dependent 
regulation - may provide key clues as to how these antigeri- 
atric tricks are accomplished. 
Richard A.  Miller 
University of Michigan 
REFERENCES 
1. Bulbrook RD, Hayward JL, Spicer CC. Relation between urinary androgen 
and corticoid secretion and subsequent breast cancer. Lancet 1971;2:395- 
398. 
2. Barrett-Conner E, Khaw K-T, Yen SSC. A prospective study of dehydroepi- 
androsterone sulfate, mortality, and cardiovascular disease. N Engl J Med 
1986;315:1519-1524. 
3. Nestler JE, Clore JN, Blackard WG. Dehydroepiandrosterone: The “missing 
link” between hyperinsulinemia and atherosclerosis? FASEB J 1992;6:3073- 
3075. 
4. Daynes RA, Araneo BA. Prevention and reversal of some age-associated 
changes in immunologic responses by supplcmental dehydroepiandrosterone 
sulfate therapy. Aging Immunol Infect Dis lYY2;3:135-154. 
structural analogs: A new class of cancer chemopreventive agents. Adv Can- 
cer Res 1988;51:391-424. 
6. Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and 
cardiovascular disease. Ann N Y Acad Sci 1995;774:259-70:259-270. 
7. Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does 
not predict cardiovascular death in postmenopausal women. The Rancho 
Bernardo Study. Circulation 1995;91:1757-1760. 
8. Zumoff B, Levin J, Rosenfeld RS et al. Abnormal 24-hr mean plasma con- 
centrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate 
in women with primary operable breast cancer. Cancer Res 1981;41:3360- 
3363. 
9. Gordon GB, Bush TL, Helzlsouer KJ et al. Relationship of serum levels of 
dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of 
developing postmenopausal breast cancer. Cancer Res 1990;503859-3862. 
10. Barrett-Connor E, Edelstein SL. A prospective study of dehydroepiandros- 
terone sulfate and cognitive function in an older population: The Rancho 
Bernardo Study. J Am Geriatr Soc 1 Y94;42:420-423. 
11. Barren-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandros- 
terone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in 
postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol 
Metab 1996;81:SY-64. 
12. Araneo B, Dowell T, Woods ML et al. DHEAS as an effective vaccine adju- 
vant in elderly humans. Proof-of-principle studies. Ann N Y Acad Sci 
5 .  Schwartz AG, Whitcomb JM, Nyce JW et al. Dehydroepiandrosterone and 
1995;774:232-48:232-248. 
13. Degelau J, Guay D, Hallgren H. The effect of DHEAS on influenza vaccina- 
14. Casson PR, Andersen RN, Herrod HG et al. Oral dehydroepiandrosterone 
tion in aging adults. J Am Geriatr Soc 1997;45:747-751. 
in physiologic doses modulates immune function in postmenopausal women. 
Am J Obstet Gynecol 1993;169:1536-1539. 
women. Potential remedial effects. Ann N Y Acad Sci 
15. Yen SS, Morales AJ, Khorram 0. Replacement of DHEA in aging men and 
1995;774:128 - 4 2  128 -142. 
16. Morales AJ, Nolan JJ, Nelson JC et al. Effects of replacement dose of dehy- 
droepiandrosterone in men and women of advancing age [published erratum 
appears in J Clin Endocrinol Metab 199s Sep;80:2799]. J Clin Endocrinol 
Metab 1994;78:1360-1367. 
17. Ebihara S, Marks T, Hudson DJ et al. Genetic control of melatonin synthesis 
in the pineal gland of the mouse. Science 1986;231:491-493. 
